RxDoctor Payments DataLook up a doctor →

Brandi Addison, DO

Endocrinology, Diabetes & Metabolism · Corpus Christi, TXNPI 1891115275

Payments from drug & device makers

$651,860in general payments, 2019–2025

Across 1,528 payments — averaging $426.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$330K
  • Corcept Therapeutics$150K
  • Novo Nordisk$98K
  • Eli Lilly$18K
  • Sanofi-aventis U.S. LLC$18K
  • AstraZeneca$18K
  • plus $20K from 48 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC565$330,392
Corcept Therapeutics215$149,658
Novo Nordisk214$97,569
Eli Lilly30$18,121
Sanofi-aventis U.S. LLC97$18,030
AstraZeneca(2 entities)51$17,828
Boehringer Ingelheim54$9,001
Janssen Research & Development, LLC5$4,908
Amgen42$838
Dexcom, Inc.25$460
Senseonics, Incorporated1$400
Abbott23$383
Novartis16$375
Bayer17$346
Amarin Pharma, Inc.17$311
Merck19$308
Antares Pharma, Inc.16$302
Nevro Corp.9$270
Xeris Pharmaceuticals, Inc.11$229
Medtronic(2 entities)7$214
Insulet Corporation10$176
Madrigal Pharmaceuticals7$174
Tandem Diabetes Care, Inc.5$146
Esperion Therapeutics, Inc.8$131
Ascendis Pharma Endocrinology Inc4$129
Recordati_rare_diseases_inc.6$125
AbbVie5$102
IBSA Pharma Inc.5$98
Neurocrine Biosciences, Inc.3$86
Amneal Pharmaceuticals LLC3$71
Mannkind Corporation3$62
Ascensia Diabetes Care US Inc.2$52
Henry Schein, Inc.3$50
Averitas Pharma Inc.2$48
Astellas Pharma US Inc3$45
Rhythm Pharmaceuticals, Inc.1$41
GSK2$34
Sequel Med Tech, LLC2$32
Johnson & Johnson2$31
Incyte Corporation2$30
Currax Pharmaceuticals LLC2$29
Blueprint Medicines Corporation1$24
Chiesi USA, Inc.1$23
Halozyme Inc1$22
BETA Bionics, Inc.2$21
Pfizer1$18
Ipsen Biopharmaceuticals, Inc1$17
Radius Health, Inc.1$16
Regeneron Healthcare Solutions, Inc.1$16
Ultragenyx Pharmaceutical Inc.1$15
Shire North American Group Inc1$14
Kowa Pharmaceuticals America, Inc.1$14
Endo Pharmaceuticals Inc.1$14
Cequr Corporation1$11

How this compares

$651,860 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$144,726
Medicare patients
349
Services billed
1,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Corpus Christi

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →